Pharmaceutical industry in China

Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th

Retrieved on: 
Tuesday, January 15, 2019
Health, Biotechnology, Pharmaceutical, General Health, Pharmaceutical industry, Medication, Health, Chemistry, Pharmaceutical industry in China

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.

Key Points: 
  • Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
  • Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.
  • Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering.
  • We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.

Pharmaceutical Industry Veteran Dr. Kurt R. Nielsen to lead Pharmaceutics International, Inc. (Pii)

Retrieved on: 
Tuesday, January 15, 2019
Catalent, Contract manufacturing organization, Pharmaceutical industry in China, Health, CNX Nifty

Dr. Nielsen is a seasoned pharmaceutical executive with over 20 years of diverse experience, most recently as the President of Lupin Somerset, responsible for all their generic and branded products.

Key Points: 
  • Dr. Nielsen is a seasoned pharmaceutical executive with over 20 years of diverse experience, most recently as the President of Lupin Somerset, responsible for all their generic and branded products.
  • Dr. Nielsen has also held positions at Catalent, where he was Senior Vice President of R&D and Chief Technology Officer, and URL Pharma where he was the Executive Vice President, Pharmaceuticals.
  • Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry.
  • In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances.

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1%

Retrieved on: 
Monday, January 14, 2019
Health, Biotechnology, Nature, Pharmaceutical industry in China, Pharmaceuticals policy, Science and technology in the People's Republic of China, Pharmaceutical industry in India, Biopharmaceutical, Compound annual growth rate, Monoclonal antibody

The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period.

Key Points: 
  • The global APIs market is estimated to reach USD 245.2 billion by 2024 from USD 182.2 billion in 2019, at a CAGR of 6.1% during the forecast period.
  • The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market.
  • The biotech APIs segment is expected to grow at the highest CAGR during the forecast period.
  • The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market.

Florida Pharmaceutical Products, Inc., Files ANDA With FDA

Retrieved on: 
Monday, January 14, 2019
Health, Pharmaceuticals policy, Generic drug, Pharmaceutical industry, Public domain, Pharmaceutical industry in China, Food and Drug Administration

This ANDA filing is the first this year for Florida Pharmaceutical Products, Inc., which plans to submit up to six total applications in 2019 and up to 12 by the end of 2020.

Key Points: 
  • This ANDA filing is the first this year for Florida Pharmaceutical Products, Inc., which plans to submit up to six total applications in 2019 and up to 12 by the end of 2020.
  • FPP will file the ANDA with the FDA and upon approval, FPP will manage product sales, marketing and distribution within the United States.
  • Florida Pharmaceutical Products, Inc. (FPP) is a Boca Raton, Florida based pharmaceutical company involved in the development of Generic Pharmaceuticals seeking to gain approval and/or license of niche generic products in a broad range of therapeutic areas for marketing and distribution in the US.
  • Florida Pharmaceutical Products, Inc., [email protected] or Bluepharma Indstria Farmacutica, S.A. at [email protected] .

China Recombinant Human Follitropin Market Report 2018-2022 Featuring Merck Serono (GONAL-f) & GeneScience Pharmaceuticals Co., Ltd. (Jinsaiheng)

Retrieved on: 
Friday, January 11, 2019
Merck, Merck Serono, Pharmaceutical industry in China, Recombinant, Peptide hormones, Recombinant proteins, Gonadotropin preparations

The "Investigation Report on China's Recombinant Human Follitropin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering

Key Points: 
  • The "Investigation Report on China's Recombinant Human Follitropin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering
    In China's end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin beta, Recombinant Human Chorionic Gonadotropin, and Recombinant Human Lutropin alfa are taking the place of small-molecule chemicals.
  • Merck Serono's Recombinant Human Follitropin (trade name: GONAL-f) was approved to be marketed in China in 2008, and GeneScience Pharmaceuticals Co., Ltd.'s Jinsaiheng was also approved in 2015.
  • By the end of 2018, all the Recombinant Human Follitropin products in China were produced by Merck Serono and GeneScience Pharmaceuticals Co., Ltd.
  • 2 Sales of Recombinant Human Follitropin in China, 2013-2017
    2.3 Sales of Recombinant Human Follitropin by Dosage Form in China, 2013-2017
    3 Analysis of Major Manufacturers of Recombinant Human Follitropin in China, 2013-2017
    3.3.1 Profile of GeneScience Pharmaceuticals Co., Ltd.
    3.3.2 Sales of GeneScience Pharmaceuticals Co., Ltd.'s Recombinant Human Follitropin in China
    4 Prices of Recombinant Human Follitropin in China, 2017-2018
    5 Prospect of China's Recombinant Human Follitropin Market, 2018-2022
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Investigation Report on China's Entecavir Market, 2018-2022 - Concepts, Sales, Manufacturers, Prices & Future Prospects - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 8, 2019
Health, Infectious diseases, Pharmaceutical, Bristol-Myers Squibb, Alkenes, Entecavir, Hepatotoxins, Purines, RTT, Nucleoside analogue, Chemistry, Health, Pharmaceutical industry in China, China, Squib

The "Investigation Report on China's Entecavir Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Entecavir Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • Developed by Bristol-Myers Squibb, Entecavir is a nucleoside analogue taken by mouth.
  • Entecavir has better and faster antiviral effect and sees less side effects and drug resistance than traditional nucleoside analogs.
  • 2 Sales of Entecavir in China, 2013-2017
    3 Analysis on Major Entecavir Manufacturers in China, 2013-2017
    4 Prices of Entecavir in China, 2017-2018
    5 Prospect of China's Entecavir Market, 2018-2022
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)
    Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190108005461/en/

China Mecobalamin Market Investigation Report, 2018-2022 - Indications, Sales, Competition, Manufacturers, Prices, Market Dynamics & Future Prospects

Retrieved on: 
Monday, January 7, 2019
Health, Eisai, Pharmaceutical industry in China, East Asia, Pharmaceutical industry, China

The "Investigation Report on China's Mecobalamin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Mecobalamin Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
  • Developed by Eisai Co., Ltd., Mecobalamin (trade name: Methycobal) was launched in Japan in the mid-1980s and introduced to China in 1996.
  • China's Mecobalamin market is dominated by Eisai China Inc., Eisai Co., Ltd., Jiangsu Sihuan Biopharmaceutical Co., Ltd., Nanjing Hailing Pharmaceutical Co., Ltd., North China Pharmaceutical Company Ltd., etc.
  • In 2017, the market share by sales value of Eisai Co., Ltd. and its subsidiary Eisai China Inc. totalled about 70%.

CANbridge Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 7, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Professional services, Banking, Finance, Pharmaceutical industry in China, Pharmaceuticals policy, Science and technology in the People's Republic of China, Health

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, Ph.D., Founder, Chairman and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 10:30 AM Pacific Time.

Key Points: 
  • CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, Ph.D., Founder, Chairman and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 10:30 AM Pacific Time.
  • Dr. Xue will give an overview of the company, including recent development program and rare disease portfolio updates.
  • CANbridge has been widely recognized as a leader in orphan diseases in China.
  • For more on CANbridge Pharmaceuticals Inc., please go to www.canbridgepharma.com .

NovaBay Pharmaceuticals Announces Preliminary 2018 Net Sales and Introduces 2019 Net Sales Guidance

Retrieved on: 
Monday, January 7, 2019
Health, Biotechnology, Optical, Pharmaceutical, salesforce.com, New York Stock Exchange, Pharmaceutical industry in China, Computing, Economy of the United States, New York City

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova for the domestic eye care market, announces 2018 net sales are expected to be $12.6 million to $12.7 million.

Key Points: 
  • NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova for the domestic eye care market, announces 2018 net sales are expected to be $12.6 million to $12.7 million.
  • The company also introduces expectations for 2019 net sales to be approximately $16.0 to $16.5 million, representing an increase of up to 30% over 2018.
  • The successful execution on these refinements gives us confidence in returning to double-digit year-over-year sales growth in 2019 and sustainable growth thereafter.
  • Last month, we hired 10 similarly highly qualified sales representatives, bringing our salesforce to 49 at the close of 2018.

Syros Announces Strategic Priorities and Expected Milestones

Retrieved on: 
Sunday, January 6, 2019
Health, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Subdivisions of Greece, Cyclades, Syros, Tourism in Greece, Medication, Pharmaceutical industry in China, Health, Aegean islands

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.

Key Points: 
  • Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today outlined its strategic priorities and expected upcoming milestones.
  • 2018 was a great year for Syros, said Nancy Simonian, M.D., Syros chief executive officer.
  • Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines.
  • Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.